Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Executive Appointment - Axogen Inc appointed Craig Swandal as Vice President of Operations, reporting to CEO Michael Dale and overseeing manufacturing, supply chain, and infrastructure strategies [1] - Craig Swandal has over 25 years of experience in global manufacturing leadership within the medical device sector, including roles at Tendyne (Abbott Labs), ATS Medical, and Gyrus Medical (Olympus) [2] - Swandal holds a Mini MBA in Medical Technology from St Thomas University and a Bachelor of Arts in Organizational Management and Communications from Concordia University [3] Equity Grant Details - Craig Swandal received an equity grant consisting of 58,000 Restricted Stock Units (RSUs) and 58,000 Performance Stock Units (PSUs) as an inducement for employment [4] - The RSUs vest over 4 years, with 50% vesting after the second year and 25% annually thereafter [5] - The PSUs vest based on company stock price performance goals between February 22, 2024, and February 22, 2027, with potential payouts ranging from 0% to 200% [5] Company Overview - Axogen is a global leader in developing surgical solutions for peripheral nerve injuries, focusing on nerve regeneration and repair [7] - The company's products are used in scheduled non-trauma procedures and emergent trauma procedures, addressing conditions like breast reconstruction, neuroma removal, and nerve decompression [8][9] Product Portfolio - Axogen's product portfolio includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, and Axoguard Nerve Cap [10] - These products are designed for peripheral nerve repair and are available in multiple countries including the United States, Canada, Germany, and the United Kingdom [10]